Anjie Biomedical Technology

Main focus: Next generation CAR-T cells

Company stage: Clinical

Diseases: Solid tumors

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Guanzhou, China

Anjie Biomedical Technology develops next generation CAR-T cells for solid tumor treatment. The company uses CRISPR to knock out PD-1 from its CAR-T cell products, in order to optimize efficiacy and safety.


HashtagAnjie Biomedical Technology Co., Ltd

Search CRISPR Medicine